South Korea · Delayed Price · Currency is KRW Cytogen Statistics
Total Valuation
Cytogen has a market cap or net worth of KRW 70.65 billion. The enterprise value is 62.85 billion.
| Market Cap | 70.65B |
| Enterprise Value | 62.85B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytogen has 23.13 million shares outstanding. The number of shares has increased by 0.54% in one year.
| Current Share Class | 23.13M |
| Shares Outstanding | 23.13M |
| Shares Change (YoY) | +0.54% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.61% |
| Owned by Institutions (%) | n/a |
| Float | 11.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.58 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.42.
| Current Ratio | 7.49 |
| Quick Ratio | 6.51 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.94 |
| Interest Coverage | -2.95 |
Financial Efficiency
Return on equity (ROE) is -27.40% and return on invested capital (ROIC) is -7.68%.
| Return on Equity (ROE) | -27.40% |
| Return on Assets (ROA) | -6.65% |
| Return on Invested Capital (ROIC) | -7.68% |
| Return on Capital Employed (ROCE) | -13.05% |
| Weighted Average Cost of Capital (WACC) | 6.78% |
| Revenue Per Employee | 652.01M |
| Profits Per Employee | -251.14M |
| Employee Count | n/a |
| Asset Turnover | 0.44 |
| Inventory Turnover | 5.80 |
Taxes
| Income Tax | -564.09M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.42% in the last 52 weeks. The beta is 0.26, so Cytogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +14.42% |
| 50-Day Moving Average | 3,170.90 |
| 200-Day Moving Average | 4,794.28 |
| Relative Strength Index (RSI) | 41.20 |
| Average Volume (20 Days) | 56,810 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cytogen had revenue of KRW 27.38 billion and -10.55 billion in losses. Loss per share was -456.81.
| Revenue | 27.38B |
| Gross Profit | 6.69B |
| Operating Income | -6.56B |
| Pretax Income | -11.11B |
| Net Income | -10.55B |
| EBITDA | -3.78B |
| EBIT | -6.56B |
| Loss Per Share | -456.81 |
Balance Sheet
The company has 22.42 billion in cash and 14.27 billion in debt, with a net cash position of 8.15 billion or 352.51 per share.
| Cash & Cash Equivalents | 22.42B |
| Total Debt | 14.27B |
| Net Cash | 8.15B |
| Net Cash Per Share | 352.51 |
| Equity (Book Value) | 33.75B |
| Book Value Per Share | 1,444.07 |
| Working Capital | 29.24B |
Cash Flow
In the last 12 months, operating cash flow was -5.61 billion and capital expenditures -1.75 billion, giving a free cash flow of -7.36 billion.
| Operating Cash Flow | -5.61B |
| Capital Expenditures | -1.75B |
| Depreciation & Amortization | 2.78B |
| Net Borrowing | -5.42B |
| Free Cash Flow | -7.36B |
| FCF Per Share | -318.25 |
Margins
Gross margin is 24.42%, with operating and profit margins of -23.94% and -38.52%.
| Gross Margin | 24.42% |
| Operating Margin | -23.94% |
| Pretax Margin | -40.57% |
| Profit Margin | -38.52% |
| EBITDA Margin | -13.80% |
| EBIT Margin | -23.94% |
| FCF Margin | n/a |
Dividends & Yields
Cytogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.54% |
| Shareholder Yield | -0.54% |
| Earnings Yield | -14.93% |
| FCF Yield | -10.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Sep 28, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Cytogen has an Altman Z-Score of 1.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.04 |
| Piotroski F-Score | 3 |